Capital City Trust Co. FL Sells 281 Shares of Amgen Inc. (NASDAQ:AMGN)

Capital City Trust Co. FL decreased its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 4.0% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 6,707 shares of the medical research company’s stock after selling 281 shares during the quarter. Capital City Trust Co. FL’s holdings in Amgen were worth $2,161,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Capital Performance Advisors LLP bought a new position in shares of Amgen in the third quarter worth $25,000. Hershey Financial Advisers LLC bought a new position in shares of Amgen in the second quarter worth $30,000. nVerses Capital LLC bought a new position in shares of Amgen in the second quarter worth $31,000. Bbjs Financial Advisors LLC bought a new position in shares of Amgen in the second quarter worth $33,000. Finally, Matrix Trust Co bought a new position in shares of Amgen in the third quarter worth $36,000. Institutional investors own 76.50% of the company’s stock.

Amgen Stock Performance

Amgen stock opened at $283.61 on Monday. The company has a current ratio of 1.32, a quick ratio of 0.96 and a debt-to-equity ratio of 7.55. The firm has a 50-day moving average of $320.85 and a 200-day moving average of $318.65. The firm has a market cap of $152.45 billion, a P/E ratio of 36.31, a P/E/G ratio of 2.53 and a beta of 0.60. Amgen Inc. has a 1-year low of $260.52 and a 1-year high of $346.85.

Amgen (NASDAQ:AMGN) last posted its earnings results on Wednesday, October 30th. The medical research company reported $5.58 earnings per share for the quarter, topping analysts’ consensus estimates of $5.11 by $0.47. The company had revenue of $8.50 billion during the quarter, compared to analyst estimates of $8.50 billion. Amgen had a net margin of 13.00% and a return on equity of 168.35%. Amgen’s revenue for the quarter was up 23.2% on a year-over-year basis. During the same period in the prior year, the business posted $4.96 earnings per share. Sell-side analysts expect that Amgen Inc. will post 19.51 EPS for the current year.

Amgen Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, December 9th. Stockholders of record on Monday, November 18th will be issued a dividend of $2.25 per share. The ex-dividend date of this dividend is Monday, November 18th. This represents a $9.00 dividend on an annualized basis and a dividend yield of 3.17%. Amgen’s dividend payout ratio is currently 115.24%.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on AMGN shares. William Blair reaffirmed an “outperform” rating on shares of Amgen in a report on Tuesday, November 12th. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $362.00 price target on shares of Amgen in a report on Thursday, September 26th. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and issued a $305.00 target price (down from $310.00) on shares of Amgen in a research report on Wednesday, August 7th. Jefferies Financial Group reiterated a “buy” rating and issued a $380.00 target price on shares of Amgen in a research report on Tuesday, November 12th. Finally, UBS Group cut their target price on shares of Amgen from $335.00 to $326.00 and set a “neutral” rating for the company in a research report on Thursday, October 31st. One investment analyst has rated the stock with a sell rating, thirteen have given a hold rating, eleven have given a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, Amgen currently has a consensus rating of “Moderate Buy” and an average price target of $333.57.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.